Sawyer & Company Inc Makes New Investment in Amgen Inc. $AMGN

Key Points

• Sawyer & Company initiated a $6.42 million Amgen stake by purchasing 15,229 shares in the third quarter, making Amgen its 12th-largest holding. Institutional investors collectively own 76.5% of the company.
• Amgen’s latest quarter exceeded expectations, with earnings of $6.29 per share and revenue of $10.05 billion, up 9.5% year over year. The company also pays a $2.52 quarterly dividend, equating to a 2.3% yield.
• Analyst sentiment remains mixed: Amgen has an overall “Hold” consensus and a $388.64 average price target, despite recent target increases and positive pipeline news, including strong Phase 3 Tezspire results. Shares recently traded at $436.21, near their 52-week high.

Sawyer & Company Inc bought a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 15,229 shares of the medical research company's stock, valued at approximately $6,419,000. Amgen accounts for 2.2% of Sawyer & Company Inc's holdings, making the stock its 12th largest position.

A number of other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its stake in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. State Street Corp grew its stake in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Amgen by 12.7% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company's stock worth $1,952,156,000 after purchasing an additional 605,928 shares in the last quarter. Bank of America Corp DE bought a new stake in Amgen in the second quarter worth approximately $1,831,903,000. Finally, Amundi lifted its stake in Amgen by 15.2% in the second quarter. Amundi now owns 3,890,189 shares of the medical research company's stock valued at $1,408,715,000 after buying an additional 512,883 shares during the period. Institutional investors own 76.50% of the company's stock.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company's stock, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Mizuho increased their price target on Amgen from $303.00 to $352.00 and gave the stock a "neutral" rating in a report on Tuesday, August 18th. Argus lifted their price objective on shares of Amgen from $375.00 to $460.00 and gave the company a "buy" rating in a research note on Wednesday, August 19th. BMO Capital Markets lowered their price objective on shares of Amgen from $450.00 to $415.00 and set a "market perform" rating for the company in a research note on Monday, October 12th. Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a research report on Sunday. Finally, Royal Bank Of Canada increased their target price on shares of Amgen from $400.00 to $430.00 and gave the stock an "outperform" rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have given a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $388.64.

Amgen Stock Down 0.6%

AMGN stock traded down $2.73 during trading on Wednesday, reaching $436.21. 685,921 shares of the stock were exchanged, compared to its average volume of 2,744,948. The firm's 50 day moving average is $416.19 and its 200 day moving average is $376.06. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market cap of $235.83 billion, a P/E ratio of 27.11, a price-to-earnings-growth ratio of 3.11 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts' expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, research analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date was Friday, August 21st. Amgen's payout ratio is 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Phase 3 Tezspire results: Amgen and AstraZeneca reported that Tezspire delivered statistically significant and clinically meaningful improvements in eosinophilic esophagitis. Results included sustained symptom improvement through 52 weeks and a 69% histologic remission rate, strengthening the drug’s potential as a growth driver if approved for this indication. Tezspire Phase 3 results
• Positive Sentiment: Analyst targets moved higher: Piper Sandler set a $457 price target, while Goldman Sachs raised its target to $481. The revisions indicate continued confidence in Amgen’s earnings outlook and pipeline, with the Goldman target implying additional upside from recent trading levels. Piper Sandler price target Goldman Sachs price target
• Positive Sentiment: Upcoming oncology presentation: Amgen will present data and host an investor webcast during the European Society for Medical Oncology Congress on October 24. New oncology data could provide further evidence that its pipeline and portfolio can support future growth. Amgen ESMO 2026 presentation
• Neutral Sentiment: Improving investment narrative: Recent coverage highlights Amgen’s earnings beat, expanding oncology and rare-disease portfolio, and strong cash generation. The company’s 2026 earnings guidance and dividend provide support, but investors still want evidence that newer products can deliver sustained growth. Amgen earnings investment story
• Negative Sentiment: Valuation and growth concerns remain: Commentary comparing Amgen with Bristol Myers Squibb notes that Amgen offers stronger top-line momentum but trades at a substantially higher valuation. With shares near their 52-week high, investors may require continued clinical and earnings execution to justify further gains. Amgen versus Bristol Myers Squibb

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.